You have 9 free searches left this month | for more free features.

pegaspargase

Showing 1 - 25 of 78

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Leukemia Trial in Portland (cyclophosphamide, cytarabine, dexamethasone)

Terminated
  • Leukemia
  • Portland, Oregon
    OHSU Knight Cancer Institute
Dec 13, 2022

Extranodal NK/T-cell Lymphoma Trial (Sugemalimab, Placebo, Pegaspargase)

Not yet recruiting
  • Extranodal NK/T-cell Lymphoma
  • Sugemalimab
  • +4 more
  • (no location specified)
Jan 17, 2023

Leukemia Trial in Germany (Amsacrine, Clofarabine, Cyclophosphamide)

Active, not recruiting
  • Leukemia
  • Bielefeld, Germany
  • +13 more
May 16, 2022

Extranodal NK/T-cell Lymphoma Trial in Beijing (Gemcitabine, Pegaspargase, Etoposide)

Recruiting
  • Extranodal NK/T-cell Lymphoma
  • Beijing, China
    Beijing Tongren Hospital
Jun 2, 2021

Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia Trial in Tianjin (Vincristine, Daunorubicin, Cyclophosphamide)

Recruiting
  • Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Dec 13, 2022

B-cell Acute Lymphoblastic Leukemia Trial in United States (Inotuzumab ozogamicin, Prednisone Pill, Daunorubicin)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • Inotuzumab ozogamicin
  • +6 more
  • Nashville, Tennessee
  • +3 more
Aug 14, 2022

Extranodal NK/T-cell Lymphoma, Nasal Type Trial in Guangzhou (Pegaspargase, Anti-PD-1 mAb, Definitive intensity-modulated

Not yet recruiting
  • Extranodal NK/T-cell Lymphoma, Nasal Type
  • Pegaspargase
  • +2 more
  • Guangzhou, Please Select, China
    Sun Yat-sen University Cancer Center
Dec 16, 2020

Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia Trial in Memphis (drug, biological, radiation)

Not yet recruiting
  • Refractory Acute Lymphoblastic Leukemia
  • Relapsed Acute Lymphoblastic Leukemia
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Aug 23, 2022

B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Lymphoblastic Lymphoma Trial

Not yet recruiting
  • B Acute Lymphoblastic Leukemia
  • +5 more
  • Biospecimen Collection
  • +4 more
  • (no location specified)
Oct 28, 2022

Acute Lymphoblastic Leukemia, Pediatric Trial in Canada, United States (Pegaspargase, Erwinia asparaginase, Cyclophosphamide)

Active, not recruiting
  • Acute Lymphoblastic Leukemia, Pediatric
  • Pegaspargase
  • +14 more
  • Boston, Massachusetts
  • +8 more
Nov 10, 2022

Leukemia Trial (cyclophosphamide, cytarabine, daunorubicin HCl)

Active, not recruiting
  • Leukemia
  • (no location specified)
Aug 16, 2021

Extranodal NK/T-cell Lymphoma, Nasal Type Trial in Shanghai (Methotrexate, Etoposide, Dexamethasone)

Active, not recruiting
  • Extranodal NK/T-cell Lymphoma, Nasal Type
  • Shanghai, Shanghai, China
    Ruijin Hospital
Aug 19, 2021

Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type, Early-stage, High-Risk Cancer Trial in Beijing (Anti-PD-1 mAb,

Recruiting
  • Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
  • +2 more
  • Anti-PD-1 monoclonal antibody
  • +4 more
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospital, Chinese Academy of Medic
Feb 23, 2022

Acute Lymphoblastic Leukemia, ALL, Childhood, ALL Trial in Chicago (Ruxolitinib, Cyclophosphamide, Cytarabine)

Recruiting
  • Acute Lymphoblastic Leukemia
  • +2 more
  • Chicago, Illinois
    University of Chicago Medical Center
Sep 14, 2021

Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood B-Lymphoblastic Lymphoma Trial in San Diego,

Completed
  • Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia
  • Recurrent Childhood B-Lymphoblastic Lymphoma
  • San Diego, California
  • +2 more
Sep 13, 2022

Drug/Agent Toxicity by Tissue/Organ, Leukemia Trial in Canada, Puerto Rico, United States (asparaginase, cyclophosphamide,

Completed
  • Drug/Agent Toxicity by Tissue/Organ
  • Leukemia
  • Boston, Massachusetts
  • +9 more
Nov 9, 2022

Extranodal NK/T-cell Lymphoma Trial (Basiliximab, Pegaspargase)

Unknown status
  • Extranodal NK/T-cell Lymphoma
  • (no location specified)
Apr 6, 2020

Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type Trial in Guangzhou (pegaspargase, Gemcitabine, Oxaliplatin)

Recruiting
  • Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
  • pegaspargase
  • +5 more
  • Guangzhou, Guangdong, China
    Department of Medical Oncology, Sun Yat-sen University Cancer Ce
Mar 12, 2021

Treatment Refusal Trial in Guangzhou (Gemcitabine, etoposide, Pegaspargase)

Unknown status
  • Treatment Refusal
  • Guangzhou, Please Select, China
    Sun Yat-sen University Cancer Center
Dec 16, 2020

Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma Trial in Australia, United States (Prednisone, Vincristine,

Recruiting
  • Acute Lymphoblastic Leukemia
  • Acute Lymphoblastic Lymphoma
  • Palo Alto, California
  • +6 more
May 2, 2022

T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma Trial in Houston (Cyclophosphamide, Cytarabine, Dexamethasone)

Recruiting
  • T Acute Lymphoblastic Leukemia
  • T Lymphoblastic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jan 11, 2023

Acute Lymphoblastic Leukemia Trial in Canada, United States (ITMHA, Dexamethasone, Mitoxantrone)

Active, not recruiting
  • Acute Lymphoblastic Leukemia
  • Los Angeles, California
  • +17 more
Jun 6, 2022

Leukemia, Lymphocytic, Lymphoblastic Lymphoma, T-cell Lymphoma Trial in United States (Palbociclib, Cytarabine, Methotrexate)

Active, not recruiting
  • Leukemia, Lymphocytic
  • +5 more
  • Birmingham, Alabama
  • +18 more
Feb 25, 2022

B Acute Lymphoblastic Leukemia, Ph-Like Acute Lymphoblastic Leukemia Trial in Duarte (Cyclophosphamide, Cytarabine, Daunorubicin

Recruiting
  • B Acute Lymphoblastic Leukemia
  • Ph-Like Acute Lymphoblastic Leukemia
  • Duarte, California
    City of Hope Medical Center
Jul 26, 2022

Acute Lymphoblastic Leukemia Trial in GuangZhou (Cladribine, G-CSF, Cytarabine)

Unknown status
  • Acute Lymphoblastic Leukemia
  • GuangZhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 18, 2019